Bitte aktivieren Sie JavaScript in Ihrem Browser um unseren Internetauftritt optimal nutzen zu können.

J Clin Endocrinol Metab., 2008; 93(8): 2978-83, PMID: 18505766

Muscle function improves during growth hormone therapy in short children born small for gestational age: results of a peripheral quantitative computed tomography study on body composition

Jahr: 2008

Schweizer R, Martin DD, Schönau E, Ranke MB
Pediatric Endocrinology Section, University Hospital for Children and Adolescents, Hoppe Seyler Strasse 1, D-72076 Tuebingen, Germany. Roland.Schweizer@med.uni-tuebingen.de

Abstract

BACKGROUND: Short small for gestational age (SGA) children can be affected by a lack of muscle mass rather than fat mass. They also face a high risk of the metabolic syndrome developing after childhood. It is not known whether low muscle mass influences muscle function. AIM: Our aim was to investigate muscle-fat distribution and muscle function before and during GH treatment in short SGA children. PATIENTS: A total of 34 prepubertal short SGA children (11 females, seven with Silver-Russell syndrome) were included in the study. Mean values were: age at GH start 7.3 yr; height sd score (SDS) -3.3; and birth weight SDS -2.7. METHODS: Investigations over 24 months on GH treatment (57 microg/kg.d) were performed. Body composition, including fat area and muscle area (MA), was assessed through peripheral quantitative computed tomography (XCT 2000; Stratec, Inc., Pforzheim, Germany). Maximal isometric grip force was performed with a Jamar dynamometer (Preston, Jackson, MI). Comparison with height-dependent reference values (SDS(Height)) was calculated. RESULTS: MA SDS(Height) at GH start was -1.8 and increased to -0.8 (P < 0.001) and -0.8, and fat area SDS(Height) decreased from -0.6 to -2.0 (P < 0.001) and -1.5 after 12 and 24 months on GH. Maximal isometric grip force SDS(Height) increased from -0.9 to 0.3 (P < 0.001) and 0.5. MA at start correlated negatively with height velocity (R = -0.54; P < 0.001) and MA SDS at start and Delta-height SDS during the first year of GH treatment (R = -0.40; P < 0.001). CONCLUSIONS: Short stature in SGA children is associated with low muscle mass and function. Supraphysiological GH doses led to a concomitant increment in height, muscle mass, and function, whereas fat mass decreased. Furthermore, body composition at GH start gives insight into GH responsiveness and the individual risk of metabolic syndrome.

Schlagworte: muscle groth hormone, growth retardation
GID: 1515; Letzte Änderung: 09.09.2008